October 9, 2014 News by Patricia Silva, PhD New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drug Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…
September 2, 2014 News by Patricia Silva, PhD Mylan’s Generic Copaxone Injection ANDA Approved for Filling by the FDA The U.S. Food and Drug Administration (FDA) accepted the abbreviated new drug application (ANDA) for filing of a Glatiramer Acetate Injection for the treatment of patients with relapsing forms of multiple sclerosis (MS).
July 25, 2014 News by Patricia Silva, PhD FDA Removes Partial Clinical Hold for CTP-354, Concert Pharmaceuticals’ Novel Drug for MS, Spasticity The U.S. Food and Drug Administration (FDA) recently notified Concert Pharmaceuticals that the company had fulfilled all necessary preclinical toxicological tests for the oral therapy CTP-354 for the treatment of multiple sclerosis, spinal cord injury, and spasticity. The authorization to administer repeated doses of the compound, in excess of 6 mg per day,…
July 18, 2014 News by Patricia Silva, PhD 8 Compounds Potentially Useful For Treating MS Discovered Using Innovative Research Tool Eight new drugs that are able to stimulate the nervous system were discovered by a research team at UC San Francisco recently. The team utilized a novel screening platform and examined the cellular effects of 1,000 chemical compounds. The scientists believe the discovery may impact the treatment of the tissue…
